Skip to content

Plain-English explainer

Wegovy Dosage Chart: 0.25 mg to 7.2 mg (Wegovy HD)

By Updated

Sources linked below.

On this page

Featured partner

CoreAge Rx

$99/mo flat

Doctor-reviewed semaglutide with one flat price and built-in human support.

Check availability
Category
Telehealth · semaglutide
Pricing
Flat monthly price
Support
Nurse + dietitian consults
Labs
No labs required

Advertising disclosure · we may earn a commission at no extra cost to you.

Partner

Direct Meds

Semaglutide as sublingual drops or a weekly shot, with the medication, nurse support and shipping in one rate and no membership.

From $249/mo sublingual

Check Direct Meds availability

FDA warning letter

The FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. It is on the public record in the FDA's warning-letter database, which we link rather than summarize. FDA warning-letter database ↗

Wegovy isn't a drug you start at full strength. It's titrated — stepped up slowly over months from a tiny starting dose to the maintenance dose that actually drives weight loss. That schedule isn't arbitrary, and it isn't a suggestion: it comes straight from the FDA label, and it exists to keep the gastrointestinal side effects tolerable while your gut adapts. Here's exactly how the escalation works, why each step matters, and what your options are if you can't comfortably reach the top.

The schedule, straight from the label

The FDA prescribing information for Wegovy lays out a five-step escalation. You initiate at 0.25 mg once weekly for 4 weeks, then follow the dosage-escalation schedule, titrating every 4 weeks to reach the maintenance dose1. Here is the full injectable chart, including the newer 7.2 mg rung:

WeeksOnce-weekly dosePen strength
1–40.25 mg (starting dose)0.25 mg/0.5 mL
5–80.5 mg0.5 mg/0.5 mL
9–121 mg1 mg/0.5 mL
13–161.7 mg1.7 mg/0.75 mL
17 onward2.4 mg (recommended maintenance; 1.7 mg also allowed)2.4 mg/0.75 mL
After 4+ weeks on 2.4 mg, if you need moreUp to 7.2 mg (Wegovy HD)7.2 mg/0.75 mL

If you take the Wegovy pill instead, the label runs a separate daily ladder in 30-day steps1:

DaysOnce-daily tablet
1–301.5 mg
31–604 mg
61–909 mg
91 onward25 mg (maintenance)

That's roughly four months of climbing before you reach the full 2.4 mg dose. This ladder belongs to Wegovy specifically — Ozempic, the oral tablets and a compounded vial each run on a different one, which we set side by side in the semaglutide dosage chart. The label is explicit that the usual recommended maintenance dosage of Wegovy injection is 2.4 mg once weekly1.

Step by step
The standard injectable ladder per the FDA label; a step can be delayed for tolerability.

Why the slow climb exists

The 0.25 mg starting dose is essentially a non-therapeutic "warm-up" — it produces little weight loss on its own. Its job is to let your body get used to the medication before the dose gets high enough to matter. Semaglutide works by slowing gastric emptying and acting on appetite centers in the brain2, and those same actions are what cause its most common side effects: nausea, vomiting, diarrhea, and constipation. Those effects are dose-related and worst at increases, which is precisely why the dose is raised in small, spaced steps rather than all at once.

The pivotal STEP 1 trial that earned Wegovy its weight-management approval used exactly this gradual 16-week escalation to the 2.4 mg dose, and even with that careful ramp, gastrointestinal effects were the most common adverse events — typically mild to moderate and concentrated early3. A dose-ranging study of semaglutide for weight loss made the trade-off concrete: higher doses produced more weight loss but also more gastrointestinal side effects, which is the entire rationale for stepping up slowly to find the highest dose you tolerate4. We cover the day-to-day management of those symptoms in our guide to semaglutide dosing and side effects.

Don't rush it — and what to do if a step is rough

The single most common mistake is trying to race to 2.4 mg. Climbing faster doesn't speed up results in a way that's worth the misery, and it sharply raises the odds of nausea and vomiting bad enough to derail treatment. The label builds in flexibility for this: if you don't tolerate an escalation step, your prescriber can delay the increase — staying at the current dose for an extra few weeks before stepping up again. That's a normal, expected adjustment, not a failure. If you're buying compounded semaglutide rather than a branded pen, an extra month at a lower dose need not cost extra either — NiceRx bills one compounded rate at every dose, though it doesn't serve Alaska, Mississippi, New Jersey or Kansas and its first month is a promotional price.

Remember

The 1.7 mg fallback maintenance dose

Not everyone can comfortably sit at 2.4 mg, and the label accounts for that. For weight reduction in adults, the maintenance dosage of Wegovy is either 1.7 mg or 2.4 mg (2.4 mg recommended) once weekly1. In plain terms: if you reach 1.7 mg and the jump to 2.4 mg brings side effects you can't live with, staying at 1.7 mg as your long-term maintenance dose is a legitimate, label-sanctioned option — not a consolation prize. You still get meaningful drug exposure; you simply prioritize tolerability. The label frames the choice as weighing treatment response against tolerability when selecting the maintenance dosage1. Where you settle also fixes your standing monthly cost — unless the plan is flat-priced, as CoreAge Rx is, charging the same at every dose with nurse and dietitian consults included, though it never names the pharmacy that compounds its semaglutide.

There's also now a higher rung beyond the standard maintenance dose: for adults who tolerate 2.4 mg for at least four weeks and need additional weight reduction, the label permits increasing to a maximum of 7.2 mg once weekly (marketed as Wegovy HD)1. That's an option for a subset of patients, not part of the routine starting ladder; who qualifies for Wegovy HD and what 7.2 mg adds has the trial numbers and price.

How the schedule fits the rest of your routine

The escalation schedule is about dose, but the mechanics of the weekly injection are worth getting right from week one — the pen, the sites, and rotating them. Our step-by-step on how to inject Wegovy walks through it. It's also worth knowing how Wegovy compares to Ozempic, which uses the same drug but tops out lower at 2 mg and is approved for diabetes rather than weight loss; we lay that out in Ozempic vs Wegovy. And if you're pricing compounded plans while you climb, the ones quoting a single figure across the whole dose range make the ladder cost-neutral — VitaraRx does that. Willow holds one monthly price for compounded semaglutide at every dose through 3.5 mg, so the climb from 0.25 mg to 2.4 mg never changes the bill, and altRx keeps one compounded semaglutide price at every dose for as long as you stay on the plan you start, though every payment there is final. Good Life Meds charges one monthly compounded semaglutide price at every dose, with no membership on top.

The bottom line

Wegovy's titration is a deliberate five-step climb — 0.25 → 0.5 → 1 → 1.7 → 2.4 mg, four weeks per step — set by the FDA label to keep side effects manageable while you reach an effective dose1. Don't rush it: slowing a step when you're struggling is built into the label, and if 2.4 mg is genuinely intolerable, 1.7 mg is an approved maintenance dose rather than a failure. Reaching the dose you can actually live with, consistently, beats sprinting to the top and quitting. (Life happens, too — if you skip a week, the rule for catching up depends on your product, which we lay out in missed or late semaglutide dose.) For the full evidence picture — how well it works and the ongoing-use reality — start with our pillar, Semaglutide: how it works, results and side effects; and if you're choosing where to get treatment, our best semaglutide providers guide shows what each program charges and what that price covers.

A few more quick ones

What is the Wegovy dose escalation schedule?

Per the FDA label, you start at 0.25 mg once weekly and step up roughly every 4 weeks: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg. The 2.4 mg dose is the recommended maintenance dose, reached after about 16 weeks of titration.

Why does Wegovy start at such a low dose?

The 0.25 mg starting dose is essentially a warm-up — it produces little weight loss but lets your body adjust to the drug. Semaglutide's GI side effects are dose-related and worst at increases, so stepping up slowly keeps nausea and vomiting tolerable.

Can I stay on 1.7 mg instead of going up to 2.4 mg?

Yes. The FDA label lists the maintenance dose for weight reduction as either 1.7 mg or 2.4 mg (2.4 mg recommended). If 2.4 mg causes side effects you can't tolerate, staying at 1.7 mg long-term is a legitimate, label-sanctioned option.

What if I can't tolerate a dose increase?

The label allows delaying an escalation step — staying at your current dose for a few extra weeks before stepping up. That's a normal adjustment your prescriber can make, not a failure. Rushing the climb mainly increases the risk of nausea and vomiting bad enough to derail treatment.

Where this comes from

Sources include clinical studies, official labeling, and company pricing pages. Company-source links below lead to our provider pricing and source checks.

  1. Novo Nordisk Pharmaceutical Industries, LP (2026). WEGOVY (semaglutide) injection / tablet — FDA Prescribing Information (Dosage and Administration; dosage escalation schedule; maintenance dosage for weight reduction). DailyMed (NLM), FDA label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. https://pubmed.ncbi.nlm.nih.gov/34626851/
  3. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/33567185/
  4. O'Neil PM, Birkenfeld AL, McGowan B, et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. https://pubmed.ncbi.nlm.nih.gov/30122305/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.